{'fraction_non_alphanumeric': 0.03699551569506727, 'fraction_numerical': 0.0515695067264574, 'mean_word_length': 4.102857142857143, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical Pharmacology of Sisomicin

Studies were conducted in 30 patients with neoplastic diseases. Twelve patients received sisomicin intramuscularly at doses of 20 mg/m2 and 40 mg/m2. The mean peak serum concentration occurred at 1 h and was 2.5 μg/ml and 4.0 μg/ml, respectively. Ten patients received intravenous sisomicin at doses of 30 mg/m2 during 30-min infusion. Mean peak serum level determined at 30 min was 5.1 μg/ml. The levels gradually decreased and at 6 h was 0.6 μg/ml. The serum half-life was 160 min. Serum levels determined in eight patients who received sisomicin by continuous infusion at doses of 30 mg/m2 every 6 h were greater than 1.4 μg/ml during the 6-h period. The urinary excretion of sisomicin during the 6-h period after intramuscular administration of 20 mg/m2 and 40 mg/m2 was 49 and 61%, respectively. The pharmacology of sisomicin is similar to gentamicin.